28 days of testosterone depletion decreases fiber CSA only in the TA muscle and only at 1.5-month-old mice. by Arik Davidyan (10450896)

Fig 3 - by Nida Mansoora (11648641)

Whsc1 deficiency decreases the expression of bone tissue-related genes in E18.5 occipital bones, sternum and sternebrae. by Yu Fei Lee (626002)

Fig 4 - by Nida Mansoora (11648641)

Fig 1 - by Nida Mansoora (11648641)

Proposed model to explain how JJX12 decreases ricin dissociation from cell surfaces. by Cristina Herrera (576490)

Autophagy inhibition decrease LAMP2 levels and survival of neuroendocrine differentiated LNCaP cells. by Cecilia Morell (729630)

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Fig 7 - by C. Vijay Reena Durai (14498259)

Transcription of feeding peptides and inflammation markers were regulated by treatment with palmitate in mHypoE-46 neurons. by Wenqing Ye (3015147)

siRNA treatment decreases ADAMTS-1 nuclear pattern in MDA-MB-231 cells. by Suély V. Silva (3233223)

“…<p>(A) Immunofluorescence shows reduced area of ADAMTS-1 (red) at nuclei with siRNA treatment. …”

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Zileuton, 5-Lipoxygenase Inhibitor, Acts as a Chemopreventive Agent in Intestinal Polyposis, by Modulating Polyp and Systemic Inflammation by Elias Gounaris (52393)

“…</p><p>Conclusions</p><p>This study demonstrates that dietary administration of 5-LO specific inhibitor in the polyposis mouse model decreases polyp burden, and suggests that Zileuton may be a potential chemo-preventive agent in patients that are high-risk of developing colon cancer.…”

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)